Gene · 6204
RPS10: ribosomal protein S10
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPS10: ribosomal protein S10. Genes, record 6204. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6204
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P46783 | Small ribosomal subunit protein eS10 | 165 | 188 | Ensembl, GeneID, HGNC |
Source UniProt
Patents27
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62079 | P46783 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 18623 | P46783 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 18623 | P46783 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74203 | P46783 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74205 | P46783 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 177174 | P46783 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 177176 | P46783 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9788 | P46783 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 242514 | P46783 | Espacenet |
| JP 2017197443 A | 2017-11-02 | 98 | P46783 | Espacenet |
1 to 10 of 27
See all 27 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants1,351
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPS10 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| R01GM067153 | Cellular factors maintaining and reversing silencing of bacterial chromatin | 6 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 4 | 2025 |
| R01AI109023 | Defining P. falciparum resistance to artemisinin-based combination therapies | 4 | 2025 |
| R01AI127456 | Poxvirus manipulation of the host cell protein synthesis machinery | 4 | 2025 |
| R35GM136323 | Dissecting the Mechanisms of Regulation and Quality Control in Ribosome Assembly and the Consequences of their Failure | 4 | 2025 |
| ZIACP010144 | Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes | 4 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 3 | 2025 |
1 to 10 of 1,351Source NIH's project files
See all 1,351 nih grantsPapers1,652
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The complete mitochondrial genome of Hemiboea subcapitata (Gesneriaceae) and comparative analysis across Lamiales. | Front Plant Sci | 2026 | 42656881 | PubTator, text mining | PubMed |
| Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. | Cell Rep | 2026 | 42284146 | PubTator, text mining | PubMed |
| Cetacean coronavirus spikes highlight S glycoprotein structural plasticity. | PLoS Pathog | 2026 | 41950284 | PubTator, text mining | PubMed |
| HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV. | Nat Commun | 2026 | 41776157 | PubTator, text mining | PubMed |
| Ribosome heterogeneity and specialization in musculoskeletal physiology and pathology. | JBMR Plus | 2026 | 41743109 | PubTator, text mining | PubMed |
| The complete genome sequencing data of Priestia aryabhattai SPCL1 isolated from a heavy metal leachate-contaminated soil in Queretaro, México. | Data Brief | 2026 | 41732370 | PubTator, text mining | PubMed |
| SCMO: a deep learning model integrating the single-cell resolution TME ecosystem and multi-omics for survival prediction in CRC patients. | J Transl Med | 2026 | 41715092 | PubTator, text mining | PubMed |
| Integrating Proteomics and Predictive Model: Elucidating the Role of Aminated Nanodiamonds in Suppressing Prostate Cancer Growth. | ACS Omega | 2026 | 41552600 | PubTator, text mining | PubMed |
| Molecular forensics: RNA degradation as a marker for postmortem interval determination. | Int J Legal Med | 2026 | 41507519 | PubTator, text mining | PubMed |
| Differential regulation of translational stress responses by herpesvirus ubiquitin deconjugases. | FEBS J | 2026 | 41076568 | PubTator, text mining | PubMed |
1 to 10 of 1,652
See all 1,652 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6204
GET https://conductscience.org/api/genes/v1/6204/patents?page=2